Journal

Antisense Oligonucleotide Tofersen Assay for SOD1 ALS New England Journal of Medicine

Antisense Oligonucleotide Tofersen Assay for SOD1 ALS New England Journal of Medicine

Abstract background The intrathecally administered antisense oligonucleotide tofersen reduces superoxide dismutase 1 (SOD1) protein synthesis and is currently being studied in patients with amyotrophic lateral sclerosis (ALS) associated with genetic mutations. SOD1 (SOD1 ALS). method Download a PDF file of the study abstract. In this phase 3 trial, we randomly assigned adults SOD1 ALS received …

Antisense Oligonucleotide Tofersen Assay for SOD1 ALS New England Journal of Medicine Read More »

Aggressive or moderate fluid resuscitation for acute pancreatitis New England Journal of Medicine

Aggressive or moderate fluid resuscitation for acute pancreatitis New England Journal of Medicine

Abstract background Early aggressive fluid rehydration is widely recommended for the treatment of acute pancreatitis, but there is limited evidence for this practice. method Download a PDF file of the study abstract. At 18 centers, we randomly assigned patients with acute pancreatitis to receive goal-directed aggressive or moderate resuscitation with lactated Ringer’s solution. Aggressive fluid …

Aggressive or moderate fluid resuscitation for acute pancreatitis New England Journal of Medicine Read More »

Anti-spiking mucosal IgA protects against SARS-CoV-2 Omicron infection New England Journal of Medicine

Anti-spiking mucosal IgA protects against SARS-CoV-2 Omicron infection New England Journal of Medicine

To the editor: Mucosal IgA may provide immunity against respiratory viruses.1 Vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) enhances mucosal IgA responses,2 Neutralizing IgA, including the B.1.1.529 (micron) variant against SARS-CoV-2, has been detected after infection with wild-type SARS-CoV-2.3 However, the potential role of mucosal IgA in preventing SARS-CoV-2 infection remains largely unknown. …

Anti-spiking mucosal IgA protects against SARS-CoV-2 Omicron infection New England Journal of Medicine Read More »

EXCLUSIVE: Medical journal expands investigation into potential heart research misconduct

EXCLUSIVE: Medical journal expands investigation into potential heart research misconduct

WASHINGTON, Sept. 13 (Reuters) – Three medical journals recently launched an independent investigation into possible data manipulation in a heart study led by Temple University researchers, Reuters has learned. Misconduct investigation adds new scrutiny. The Journal of Molecular and Cellular Cardiology and the Journal of Biochemistry are investigating five papers written by Temple scientists, the …

EXCLUSIVE: Medical journal expands investigation into potential heart research misconduct Read More »

Enhanced Durability of mRNA Vaccines Against SARS-CoV-2 BA.2.12.1, BA.4, and BA.5 Subvariants | New England Journal of Medicine

Enhanced Durability of mRNA Vaccines Against SARS-CoV-2 BA.2.12.1, BA.4, and BA.5 Subvariants | New England Journal of Medicine

To the editor: Growing focus on long-term efficacy of messenger RNA (mRNA)-boosted vaccines against coronavirus disease 2019 (Covid-19)1 The recent emergence of B.1.1.529 (omicron) subvariants BA.2.12.1 and BA.4 and BA.5 (hereafter BA.4/5) of severe acute respiratory syndrome coronavirus 2 (SARS) has exacerbated This case-CoV-2), with a high degree of immune escape.2 To address this question, …

Enhanced Durability of mRNA Vaccines Against SARS-CoV-2 BA.2.12.1, BA.4, and BA.5 Subvariants | New England Journal of Medicine Read More »

Risk of infection with BA.5 in people exposed to previous SARS-CoV-2 variants New England Journal of Medicine

Risk of infection with BA.5 in people exposed to previous SARS-CoV-2 variants New England Journal of Medicine

To the editor: In recent months, omicron (B.1.1.529) has emerged as a major variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), exhibiting some degree of immune evasion.1 The original omicron sub-variants BA.1 and BA.2 are gradually being replaced by BA.5 in many countries, possibly due to greater transmissibility and partial escape from BA.1 and …

Risk of infection with BA.5 in people exposed to previous SARS-CoV-2 variants New England Journal of Medicine Read More »

Bedaquiline-Pretomanid-Linezolid regimen for drug-resistant tuberculosis | New England Journal of Medicine

Bedaquiline-Pretomanid-Linezolid regimen for drug-resistant tuberculosis | New England Journal of Medicine

Test design ZeNix is ​​a partially blinded, randomized trial that enrolled participants with extensively drug-resistant (XDR) TB, pre-XDR TB, or rifampicin-resistant TB. Participants with XDR tuberculosis were resistant to rifampicin, a fluoroquinolone, and an aminoglycoside. Pre-XDR TB was defined as resistance to rifampicin plus resistance to fluoroquinolones or aminoglycosides.Rifampicin-resistant TB is defined as Mycobacterium tuberculosis …

Bedaquiline-Pretomanid-Linezolid regimen for drug-resistant tuberculosis | New England Journal of Medicine Read More »

Efficacy and safety of extravascular implantable cardioverter-defibrillators New England Journal of Medicine

Efficacy and safety of extravascular implantable cardioverter-defibrillators New England Journal of Medicine

Abstract background Extravascular implantable cardioverter-defibrillators (ICDs) implant a lead under the sternum to achieve pause-prevention pacing, anti-tachycardia pacing, and defibrillation energy similar to transvenous ICDs. The safety and efficacy of extravascular ICDs are unknown. method We conducted a prospective, single-arm, non-randomized, premarketing global clinical study involving patients with ICD indications I or IIa, all of …

Efficacy and safety of extravascular implantable cardioverter-defibrillators New England Journal of Medicine Read More »

Acetazolamide in the treatment of acute decompensated heart failure with volume overload New England Journal of Medicine

Acetazolamide in the treatment of acute decompensated heart failure with volume overload New England Journal of Medicine

Abstract background Could acetazolamide, a carbonic anhydrase inhibitor that reduces proximal renal tubular sodium reabsorption, improve the efficiency of loop diuretics, potentially leading to more and faster volume overload in acute decompensated heart failure patients Reduce congestion, it is not known. method In this multicenter, parallel group, double-blind, randomized, placebo-controlled trial, we will treat patients …

Acetazolamide in the treatment of acute decompensated heart failure with volume overload New England Journal of Medicine Read More »